In Preparation for Biosimilar “Switch” Policy: How to Mitigate the Nocebo Effect

Abstract

Keywords

Get full access to this article

View all access options for this article.

References

Colloca

Panaccione

Murphy

. The clinical implications of nocebo effects for Biosimilar therapy. Front Pharmacol. 2019;10:1372. doi:10.3389/fphar.2019.01372

31849647

Martinez-Cabriales

SA.

Manion

Shear

. Biosimilars: promises made. Promises Kept? J Cutan Med Surg. 2021;25(3):241-242.doi:10.1177/12034754211007814

Barbier

Ebbers

HC.

Declerck

Simoens

Vulto

AG.

Huys

. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734-755.doi:10.1002/cpt.1836

32236956

Tweehuysen

van den Bemt

BJF.

van Ingen

et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60-68.doi:10.1002/art.40324

29045077